Rigel Provides Business Update and 2025 Outlook

Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of$31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of$8.1 million R289 granted Orphan Drug designation by the FDA for the treatment of MDS Rigel anticipates 2025 total revenue of approximately $200 to$210 millionSOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnol ...